Microbiome Collaboration and Licensing Agreements Trends Report 2024 and Directory of 244 Deals Signed Since 2016 by Company, Deal Type, Upfront, Milestone, Royalties and Therapy Area

Core Insights - The report titled "Microbiome Collaboration and Licensing Deals 2016-2024" provides a comprehensive overview of 244 microbiome deals announced since 2016, including financial terms and links to deal records [2][4][5] - It offers unprecedented access to microbiome deals made by leading biopharma companies, detailing the motivations and structures behind these agreements [3][4] Report Scope - The report analyzes contract agreements to facilitate due diligence, covering deal trends, financial terms, and a directory of deals organized by company, deal type, and therapeutic target [6][7] - It includes insights into the payment structures, exclusivity rights, and responsibilities for commercialization and development within microbiome deals [8][12] Trends and Analysis - The report highlights trends in microbiome deal-making in the biopharma industry, showcasing leading deals by value and identifying the most active dealmakers [8][10] - It provides a detailed analysis of microbiome deals over the years, including upfront payments, milestone payments, and royalty rates [12][12] Key Topics Covered - The report is structured into several chapters, including an executive summary, trends in microbiome deal-making, leading deals, and a comprehensive directory of microbiome contracts [9][10] - It also addresses key contractual clauses, jurisdictional preferences, and boilerplate clauses that vary across different deals [11]